Predicting the prognosis of undifferentiated pleomorphic soft tissue sarcoma: a 20-year experience of 266 cases.
Aged
Chemotherapy, Adjuvant
/ methods
Combined Modality Therapy
/ methods
Female
Histiocytoma, Malignant Fibrous
/ classification
Humans
Lower Extremity
/ pathology
Male
Margins of Excision
Middle Aged
Neoplasm Metastasis
/ pathology
Neoplasm Recurrence, Local
/ pathology
Prognosis
Retrospective Studies
Sarcoma
/ pathology
Soft Tissue Neoplasms
/ pathology
Survival Rate
Upper Extremity
/ pathology
malignant fibrous histiocytoma
sarcoma
soft tissue sarcoma
undifferentiated pleomorphic sarcoma
Journal
ANZ journal of surgery
ISSN: 1445-2197
Titre abrégé: ANZ J Surg
Pays: Australia
ID NLM: 101086634
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
12
11
2018
revised:
06
05
2019
accepted:
11
06
2019
pubmed:
1
8
2019
medline:
2
9
2020
entrez:
1
8
2019
Statut:
ppublish
Résumé
Undifferentiated pleomorphic sarcoma (UPS) is a rare malignant tumour of mesenchymal origin, which was conceived following re-classification of malignant fibrous histiocytoma (MFH). The objective of this study is to determine prognostic factors for the outcome of UPS, following multi-modal treatment. Data of UPS tumours from 1996 to 2016 were collected, totalling 266 unique UPS patients. Median follow-up was 7.8 years. All tumours were retrospectively analysed for prognostic factors of the disease, including local recurrence (LR) and metastatic disease (MD) at diagnosis, tumour size, grade, location and depth, patient age, adjuvant therapy and surgical margin. Overall survival (OS), post-treatment LR and metastatic-free survival were assessed as outcomes. The 5- and 10-year OS rates for all ages were 60% and 48%, respectively, with a median survival time of 10.1 years. Multivariate analysis revealed that the adverse prognostic factors associated with decreased OS were older age (P < 0.001; hazard ratio 1.03) and MD at diagnosis (P = 0.001; 2.89), with upper extremity tumours being favourable (P = 0.043; 2.30). Poor prognosis for post-operative LR was associated with older age (P = 0.046; 1.03) and positive surgical margins (P = 0.028; 2.68). Increased post-treatment MD was seen in patients with large tumours (5-9 cm (P < 0.001; 4.42), ≥10 cm (P < 0.001; 6.80)) and MD at diagnosis (P < 0.001; 3.99), adjuvant therapy was favourable, shown to reduce MD (P < 0.001; 0.34). UPS is a high-grade soft tissue sarcoma, for which surgery striving for negative margins, with radiotherapy, is the treatment of choice. Older age, lower extremity location, MD at presentation, large size and positive surgical margins, were unfavourable.
Sections du résumé
BACKGROUND
Undifferentiated pleomorphic sarcoma (UPS) is a rare malignant tumour of mesenchymal origin, which was conceived following re-classification of malignant fibrous histiocytoma (MFH). The objective of this study is to determine prognostic factors for the outcome of UPS, following multi-modal treatment.
METHODS
Data of UPS tumours from 1996 to 2016 were collected, totalling 266 unique UPS patients. Median follow-up was 7.8 years. All tumours were retrospectively analysed for prognostic factors of the disease, including local recurrence (LR) and metastatic disease (MD) at diagnosis, tumour size, grade, location and depth, patient age, adjuvant therapy and surgical margin. Overall survival (OS), post-treatment LR and metastatic-free survival were assessed as outcomes.
RESULTS
The 5- and 10-year OS rates for all ages were 60% and 48%, respectively, with a median survival time of 10.1 years. Multivariate analysis revealed that the adverse prognostic factors associated with decreased OS were older age (P < 0.001; hazard ratio 1.03) and MD at diagnosis (P = 0.001; 2.89), with upper extremity tumours being favourable (P = 0.043; 2.30). Poor prognosis for post-operative LR was associated with older age (P = 0.046; 1.03) and positive surgical margins (P = 0.028; 2.68). Increased post-treatment MD was seen in patients with large tumours (5-9 cm (P < 0.001; 4.42), ≥10 cm (P < 0.001; 6.80)) and MD at diagnosis (P < 0.001; 3.99), adjuvant therapy was favourable, shown to reduce MD (P < 0.001; 0.34).
CONCLUSIONS
UPS is a high-grade soft tissue sarcoma, for which surgery striving for negative margins, with radiotherapy, is the treatment of choice. Older age, lower extremity location, MD at presentation, large size and positive surgical margins, were unfavourable.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1045-1050Informations de copyright
© 2019 Royal Australasian College of Surgeons.
Références
Singer S, Demetri GD, Baldini EH, Fletcher CD. Management of soft-tissue sarcomas: an overview and update. Lancet Oncol. 2000; 1: 75-85.
Ozzello L, Stout AP, Murray MR. Cultural characteristics of malignant histiocytomas and fibrous xanthomas. Cancer 1963; 16: 331-44.
Weiss SW, Enzinger FM. Malignant fibrous histiocytoma. An analysis of 200 cases. Cancer 1978; 41: 2250-66.
Fletcher CD, Unni KK, Mertens F. Pathology and Genetics of Tumours of Soft Tissues and Bone. WHO Classification of Tumours, 3rd edn. Lyon: IARC Press, 2002.
Fletcher CD, Bridge JA, Hogendoorn PCW, Mertens F. WHO Classification of Tumours of Soft Tissue and Bone, 4th edn. Lyon: IARC Press, 2013.
Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J. Clin. Oncol. 2003; 21: 2719-25.
O'Connor MI, Pritchard DJ, Gunderson LL. Integration of limb-sparing surgery, brachytherapy, and external-beam irradiation in the treatment of soft-tissue sarcomas. Clin. Orthop. Relat. Res. 1993; 289: 73-80.
O'Sullivan B, Davis AM, Turcotte R et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002; 359: 2235-41.
Davis AM, O'Sullivan B, Turcotte R et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother. Oncol. 2005; 75: 48-53.
Belal A, Kandil A, Allam A et al. Malignant fibrous histiocytoma: a retrospective study of 109 cases. Am. J. Clin. Oncol. 2002; 25: 16-22.
Fletcher CD, Gustafson P, Rydholm A, Willen H, Akerman M. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J. Clin. Oncol. 2001; 19: 3045-50.
Gibbs JF, Huang PP, Lee RJ et al. Malignant fibrous histiocytoma: an institutional review. Cancer Invest. 2001; 19: 23-7.
Hsu HC, Huang EY, Wang CJ. Treatment results and prognostic factors in patients with malignant fibrous histiocytoma. Acta Oncol. 2004; 43: 530-5.
Le Doussal V, Coindre JM, Leroux A et al. Prognostic factors for patients with localized primary malignant fibrous histiocytoma: a multicenter study of 216 patients with multivariate analysis. Cancer 1996; 77: 1823-30.
Pezzi CM, Rawlings MS Jr, Esgro JJ, Pollock RE, Romsdahl MM. Prognostic factors in 227 patients with malignant fibrous histiocytoma. Cancer 1992; 69: 2098-103.
Salo JC, Lewis JJ, Woodruff JM, Leung DH, Brennan MF. Malignant fibrous histiocytoma of the extremity. Cancer 1999; 85: 1765-72.
Vasileios KA, Eward WC, Brigman BE. Surgical treatment and prognosis in patients with high-grade soft tissue malignant fibrous histiocytoma of the extremities. Arch. Orthop. Trauma Surg. 2012; 132: 955-61.
Zagars GK, Mullen JR, Pollack A. Malignant fibrous histiocytoma: outcome and prognostic factors following conservation surgery and radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1996; 34: 983-94.
Lehnhardt M, Daigeler A, Homann HH et al. MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities - an analysis of 140 patients. Langenbecks Arch. Surg. 2009; 394: 313-20.
Fletcher CD. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology 2006; 48: 3-12.
Randall RL, Albritton KH, Ferney BJ, Layfield L. Malignant fibrous histiocytoma of soft tissue: an abandoned diagnosis. Am. J. Orthop. 2004; 33: 602-8.
Lee YF, John M, Edwards S et al. Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling. Br. J. Cancer 2003; 88: 510-5.
Nakayama R, Nemoto T, Takahashi H et al. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod. Pathol. 2007; 20: 749-59.
Nielsen TO, West RB, Linn SC et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 2002; 359: 1301-7.
Rosenberg SA, Tepper J, Glatstein E et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann. Surg. 1982; 196: 305-15.